We will develop tissue-engineered complex model systems in 3D, which contain distinct cell
populations, modelling complex tissues. We will use these to evaluate action of nanotargeted
agents directed against critical pathways controlling cell growth and proliferation.
Incorporating immune cells is the key innovation for this model. Cancer progression within
the complex milieu will be interrogated at the tissue, cell and genetic level. New generation
biologics, acting directly against cancer cells and indirectly by recruiting immune cells, will be
tested in immunocompetent models. Novel biologic-nanoparticle conjugates serving as dual
imaging/therapeutic agents will map drug-cell interactions and drug fate within tissues.
Moreno-Moral A et al., Changes in macrophage transcriptome associate with systemic
sclerosis and mediate GSDMA contribution to disease risk. Ann Rheum Dis 2019 Jan. In Press
Taher T et al., Defective regulation of autoreactive IL-6 producing transitional B cells is
associated with disease in patients with systemic sclerosis. Arthritis Rheumatol 2017 Nov 28.
[Epub ahead of print]
Magdeldin T et al., Engineering a vascularised 3D in vitro model of
cancer progression. Scientific Reports 2017 doi:10.1038/srep44045
Ramesh BS et al.,Detection of Cell Surface Calreticulin as a Potential Cancer Biomarker
Using Near-Infrared Emitting Gold Nanoclusters. Nanotech 2016 27(28):285101. doi:
Lopez-Davila V et al., Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles
as AZD6244 nanocarriers in a 3D colorectal cancer in vitro
model. Nanomedicine 2016 11(4), 331-44, doi: 10.2217/nnm.15.206.